An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
← catalyst calendarNCT07583563 · readout ≤ 1,045 d
Sponsored by Camurus AB (industry) · CAMX.ST — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
200estimated
Sites
6
Countries
Germany, United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-05 | actual | When the study began enrolling |
| Primary completion | Jun 2029 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jun 2029 | estimated | The whole study's end, after follow-up |
| First posted | 2026-05-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acromegaly
Intervention
- Drug: Octreotide subcutaneous depot
Primary outcome
what the primary-completion date above is the date OFIncidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information.
measured From enrollment to the end of treatment at 2 years
Permalink · CAMX.ST's whole pipeline · Catalyst calendar · Every registered study · What changed